Results 31 to 40 of about 536 (130)

Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection. [PDF]

PLoS Computational Biology, 2015
Recent discoveries of direct acting antivirals against Hepatitis C virus (HCV) have raised hopes of effective treatment via combination therapies.
Ruian Ke, Claude Loverdo, Hangfei Qi, Ren Sun, James O Lloyd-Smith   +4 more
doaj   +1 more source

Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis [PDF]

, 2015
IMPORTANCE: Effective and well-tolerated, interferon-free regimens are needed for treatment of patients with chronic hepatitis C virus (HCV) infection and cirrhosis. OBJECTIVE: All-oral therapy with daclatasvir (nonstructural protein 5A [NS5A] inhibitor),
Everson, G, Muir, Andrew J., McPhee, Fiona, Poordad, Fred, Dore, Gregory J, Yin, Philip D., Ramji, A, Yang, R, Ghesquiere, W, Pockros, Paul J, Hughes, Eric A., Reau, N, Thompson, AJ, Pockros, Paul J., Swenson, E. Scott, Pockros, PJ, Kwo, P, Ghesquiere, Wayne, Vierling, J, Tran, Albert, Reau, Nancy, Muir, Andrew J, Yang, Rong, Everson, Gregory, Tran, A, Lalezari, Jacob, Thompson, Alexander J, Herring, R, Lalezari, J, Hézode, Christophe, Vierling, John, Yozviak, J, Ramji, Alnoor, Yozviak, Joseph, Freilich, B, Sheikh, A, Cooper, James, Hézode, C, Stuart, K, Poordad, F, Hughes, EA, Dore, Gregory J., Swenson, ES, Swenson, E Scott, Freilich, Bradley, Yin, Philip D, Sheikh, Aasim, Muir, AJ, Kwo, Paul, Yozviak, Joseph L, DO, FACP, Hughes, Eric A, McPhee, F, Thompson, Alexander J., Dore, GJ ; https://orcid.org/, Herring, Robert, Stuart, Katherine, Yin, PD, Cooper, J   +57 more
core   +2 more sources

Asunaprevir-containing regimens for the treatment of hepatitis C virus infection

, 2017
Chronic hepatitis C virus (HCV) infection has been a tremendous health burden worldwide with an annual mortality of 300,000 people due to decompensated cirrhosis or hepatocellular carcinoma.
Yang, Sheng-Shun;Kao, Jia-Horng, 高嘉宏   +1 more
core   +1 more source

Evaluating Andrographolide as a Potent Inhibitor of NS3-4A Protease and Its Drug-Resistant Mutants Using In Silico Approaches

Advances in Virology, 2015
Current combination therapy of PEG-INF and ribavirin against the Hepatitis C Virus (HCV) genotype-1 infections is ineffective in maintaining sustained viral response in 50% of the infection cases.
Vivek Chandramohan, Anubhav Kaphle, Mamatha Chekuri, Sindhu Gangarudraiah, Gowrishankar Bychapur Siddaiah   +4 more
doaj   +1 more source

Pharmacophore anchor models of flaviviral NS3 proteases lead to drug repurposing for DENV infection

BMC Bioinformatics, 2017
Background Viruses of the flaviviridae family are responsible for some of the major infectious viral diseases around the world and there is an urgent need for drug development for these diseases.
Nikhil Pathak, Mei-Ling Lai, Wen-Yu Chen, Betty-Wu Hsieh, Guann-Yi Yu, Jinn-Moon Yang   +5 more
doaj   +1 more source

Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C

, 2014
International audienceBackground & AimsAsunaprevir is a selective HCV NS3 protease inhibitor, active against genotypes 1, 4, 5, and 6 in vitro. We evaluated asunaprevir plus peginterferon alfa-2a/ribavirin (PegIFNα/RBV) for genotype 1 and 4 chronic HCV ...
Cohen, David, Hughes, Eric, Ratziu, Vlad, Bessone, Fernando, Mendez, Patricia, Younes, Ziad, Bronowicki, Jean-Pierre, Thuluvath, Paul, Martorell, Claudia, Terg, Ruben, He, Bing, Pol, Stanislas, Hernandez, Dennis, Mcphee, Fiona, Eley, Timothy, Yu, Fei, Gadano, Adrian   +16 more
core   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, Volume 13, Issue 35, 24 June 2026.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection [PDF]

Clinical and Molecular Hepatology, 2016
Background/Aims: The treatment strategy for hepatitis C virus (HCV) has been changing rapidly since the introduction of direct-acting antivirals such as daclatasvir (DCV) and asunaprevir (ASV).
Hee Chul Nam, Hae Lim Lee, Hyun Yang, Myeong Jun Song   +3 more
doaj   +1 more source

Comparison of Interferon‐Based and Interferon‐Free Treatments on the Prognosis of Hepatocellular Carcinoma After Hepatitis C Virus‐Sustained Virological Response: A Multicenter Study

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT Aim We examine the impact of interferon (IFN)‐based and IFN‐free treatment on the prognosis of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) sustained virological response (SVR). Methods Clinical information was collected on 311 cases of HCC after HCV‐SVR from 16 facilities affiliated with the Kyushu Liver Surgery Study Group ...
Shinji Itoh, Norifumi Iseda, Tomoharu Yoshizumi, Takao Ide, Hirokazu Noshiro, Hisamune Sakai, Toru Hisaka, Masao Nakashima, Hiroaki Nagano, Hirohisa Okabe, Hiromitsu Hayashi, Atsushi Miyoshi, Kenji Kitahara, Yuko Takami, Atsushi Nanashima, Tamotsu Kuroki, Yuichi Endo, Kohji Okamoto, Masatoshi Kajiwara, Masahiko Sakoda, Toru Beppu, Mitsuhisa Takatsuki, Susumu Eguchi   +22 more
wiley   +1 more source

Multivariate logistic regression analysis to identify factors associated with liver injuries in patients with genotype 1b HCV receiving daclatasvir plus asunaprevir therapy.

, 2018
Multivariate logistic regression analysis to identify factors associated with liver injuries in patients with genotype 1b HCV receiving daclatasvir plus asunaprevir therapy.
Kayoko Sugawara (5848991), Yukinori Imai (5849006), Nobuaki Nakayama (5849003), Masamitsu Nakao (5848994), Mie Inao (5849000), Satoshi Mochida (156566), Jun-ichi Kouyama (661243), Daisuke Motoya (5848997), Yoshihito Uchida (661242), Kayoko Naiki (661244), Tomoaki Tomiya (479370)   +10 more
core   +1 more source